These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
5. Overview of drug therapy for multiple myeloma. Saunders G J Oncol Pharm Pract; 2005 Sep; 11(3):83-100. PubMed ID: 16390597 [TBL] [Abstract][Full Text] [Related]
6. The emerging role of arsenic trioxide as an immunomodulatory agent in the management of multiple myeloma. Kalmadi SR; Hussein MA Acta Haematol; 2006; 116(1):1-7. PubMed ID: 16809883 [TBL] [Abstract][Full Text] [Related]
7. Sequential vincristine, adriamycin, dexamethasone (VAD) followed by bortezomib, thalidomide, dexamethasone (VTD) as induction, followed by high-dose therapy with autologous stem cell transplant and consolidation therapy with bortezomib for newly diagnosed multiple myeloma: results of a phase II trial. Kim HJ; Yoon SS; Lee DS; Sohn SK; Eom HS; Lee JL; Chung JS; Kim K; Suh C; Won JH; Kim JS; Park JS; Kang HJ; Seong CM; Kim CS; Lee SJ; Lee JH Ann Hematol; 2012 Feb; 91(2):249-56. PubMed ID: 21789621 [TBL] [Abstract][Full Text] [Related]
8. Targeted therapy in multiple myeloma. Chng WJ; Lau LG; Yusof N; Mow BM Cancer Control; 2005 Apr; 12(2):91-104. PubMed ID: 15855892 [TBL] [Abstract][Full Text] [Related]
9. Diagnosis and therapy of multiple myeloma. Palumbo A; Cerrato C Korean J Intern Med; 2013 May; 28(3):263-73. PubMed ID: 23682217 [TBL] [Abstract][Full Text] [Related]
10. New drugs in multiple myeloma. Berenson JR; Yellin O Curr Opin Support Palliat Care; 2008 Sep; 2(3):204-10. PubMed ID: 18685422 [TBL] [Abstract][Full Text] [Related]
11. New treatments for multiple myeloma. Richardson PG; Schlossman R; Hideshima T; Anderson KC Oncology (Williston Park); 2005 Dec; 19(14):1781-92; discussion 1792, 1795-7. PubMed ID: 16506632 [TBL] [Abstract][Full Text] [Related]
13. Bortezomib treatment followed by a second non-myeloablative allogeneic stem cell transplant in two previously autografted patients with multiple myeloma relapse. Mattei D; Mordini N; Vigna Taglianti R; Bruno B; Rapezzi D; Gallamini A Haematologica; 2005 Jun; 90(6):861-2. PubMed ID: 15951306 [TBL] [Abstract][Full Text] [Related]
16. The emerging role of novel therapies for the treatment of relapsed myeloma. Richardson PG; Hideshima T; Mitsiades C; Anderson KC J Natl Compr Canc Netw; 2007 Feb; 5(2):149-62. PubMed ID: 17335684 [TBL] [Abstract][Full Text] [Related]
17. Novel agents to improve outcome of allogeneic transplantation for patients with multiple myeloma. Kortüm M; Knop S; Einsele H Future Oncol; 2011 Jan; 7(1):135-43. PubMed ID: 21174544 [TBL] [Abstract][Full Text] [Related]
18. Frontline therapy for multiple myeloma: a concise review of the evidence based on randomized clinical trials. Yaqub S; Ballester G; Ballester O Cancer Invest; 2013 Oct; 31(8):529-37. PubMed ID: 24083815 [TBL] [Abstract][Full Text] [Related]